Fda Panel

• An FDA advisory panel is meeting this week to determine if compounding pharmacies should be permitted to offer seven synthetic peptides. • The panel must weigh whether regulated compounding pharmacies provide a safer alternative to the "gray-market" versions currently used by enthusiasts. • The decision is critical due to significant concerns regarding the safety of these largely unproven peptides and potential conflicts of interest.

• An FDA advisory panel began a two-day meeting on Thursday to review more than six types of peptides currently used in wellness trends. • These substances are under scrutiny because there is little scientific evidence to prove they are safe or effective for human use. • The review is critical as these unproven peptides have gained popularity despite a lack of formal regulatory approval.

• Morning Rounds reports on several critical health updates, including the legal and administrative status of service members who refused the Covid-19 vaccine. • The briefing highlights a current Ebola outbreak, which is described as the fastest-growing in history, signaling an urgent public health crisis. • These stories underscore the ongoing tension between military mandates and personal health choices, as well as the volatility of global infectious disease containment.

Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and olderUS health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Continue reading...

• An FDA advisory panel will convene this Thursday to determine which Covid-19 strain vaccine manufacturers should target for the 2026-2027 season. • The meeting occurs as the United States continues to navigate a shifting vaccine infrastructure and evolving public health needs. • Separately, an experimental Ebola vaccine developed by an Oxford team is approaching the production phase for upcoming clinical trials.

• An FDA advisory panel overwhelmingly recommended on Thursday that manufacturers base the 2026-2027 Covid-19 vaccine formulas on the dominant XFG variant. • This recommendation ensures that future vaccine iterations remain effective against evolving strains of the virus to maintain public health protections. • Separately, World Health Organization experts are urging that all prevention and treatment products for the Ebola Bundibugyo virus be used exclusively within clinical trials.